Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE)

Jolien E. J. Boesten*, Janneke Kaper, Henri E. J. H. Stoffers, Abraham A. Kroon, Onno C. P. van Schayck

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)
Original languageEnglish
Pages (from-to)521-527
JournalFamily Practice
Issue number5
Publication statusPublished - Oct 2012


  • Atherosclerosis
  • cardiovascular disorders
  • diabetes
  • drug reactions
  • hypertension
  • insulin resistance
  • pharmacology
  • primary care
  • quality of life

Cite this